Janux Therapeutics
JANX
49 hedge funds and large institutions have $400M invested in Janux Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 0 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
13% more capital invested
Capital invested by funds: $353M → $400M (+$47.3M)
11% more funds holding
Funds holding: 44 → 49 (+5)
1.5% more ownership
Funds ownership: 69.45% → 70.95% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.63M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.52M |
| 3 |
Morgan Stanley
New York
|
+$1.52M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.48M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$680K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$2.24M |
| 2 |
Cerity Partners
New York
|
-$601K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$395K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$138K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$26.7K |
JANX Hedge Fund Activity: Q3 2022 in Review
49 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2022, worth a combined $400M — up 13% from $353M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new JANX positions and 0 closed out — a net gain of 5 holders — while 17 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $5.63M. The largest seller was Janus Henderson Group, cutting an estimated $2.24M.
- 49 institutional investors held Janux Therapeutics (JANX) as of Q3 2022, up from 44 in Q2 2022.
- Funds reported $400M of Janux Therapeutics stock for Q3 2022, up 13% quarter-over-quarter.
- 5 funds opened new Janux Therapeutics positions in Q3 2022 and 0 closed out, a net change of +5 holders.
- The largest Janux Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $5.63M added.
- The largest Janux Therapeutics seller in Q3 2022 was Janus Henderson Group, an estimated $2.24M sold.
Based on aggregated 13F filings for Q3 2022.